Articles

Key View

• UK drug shortages will likely persist due to ongoing post-Brexit access challenges, alongside wider regional supply chain issues. 
• The UK's pharmaceutical sector will continue to present a less attractive prospect for investment compared to EU markets.
• Amidst Brexit's complexities, the UK government will continue to introduce new measures to

Key View: Over 2024, we forecast total arrivals to Mauritius to reach 1.5mn, up from 1.3mn arrivals in 2023, growing by 14.2% y-o-y. We expect Mauritius’ 2024 arrivals to fully recover to pre-Covid levels in 2019, while surpassing the historic peak in 2018. Arrivals will continue to increase over the medium term (2024-2028) with the market’s beach

Key View

• Malaysia’s medical device sales will expand over the medium term, supported by growing health spending and ambitions to increase domestic production.
• Despite efforts to increase domestic production, Malaysia will continue to rely heavily on imported orthopaedic and dental products.
• Malaysia’s growing position as a leading medical tourism

Key View

• We have revised up our forecast for Brazilian real GDP growth in 2024 from 1.6% to an above-consensus 2.1%, while we have modestly lowered our 2025 projection from 2.0% to 1.8%. 
• Data for the early part of 2024 have generally been quite strong, with domestic demand remaining resilient. Consumer spending in particular has benefitted from a

Key View

• We forecast that real GDP will expand by 3.1% in Barbados in 2024, a solid performance given strong base effects.
• Private consumption will overwhelmingly be the main growth driver, underpinned by the strong performance of the tourism sector boosting employment and wages in the sector.
• The largest risk to growth is posed by any geopolitically

Key View: Our outlook for German consumer spending over 2024 shows a slight yet modest rebound yet remains below pre-pandemic levels. Consumer confidence is stable but subdued, with retail sales weak amid ongoing economic challenges. Inflation pressures are expected to ease, while the labour market is relatively tight. Government interventions

The Latest: On April 22, 2024, the European Commission (EC) granted approval to Samsung Bioepis’s Pyzchiva (ustekinumab), a biosimilar to Johnson & Johnson’s Stelara (ustekinumab), thereby broadening the range of treatment options for patients with chronic inflammatory conditions. Pyzchiva is indicated for the treatment of plaque psoriasis

The Latest: In May 2024, AB Living which is a Spain-based property development group announced plans to open a new Almare resort in Isla Mujeres, Mexico in partnership with US-based hotels and resorts company Marriott International. The all-inclusive adult-only resort will be part of Marriott's Luxury Collection and will include 150-rooms, with

Latest Development: Data released on April 25 showed South Korea’s real GDP expanding in Q124 by a seasonally-adjusted 1.3% q-o-q, accelerating from 0.6% in Q423. This corresponded to a 3.4% y-o-y growth.

Forecast Implications: The outturn surprised significantly to the upside, surpassing both our and the consensus estimate of a 2.4% y-o-y

Key View

• Nigeria is reportedly set to intensify the legal protection of broadband infrastructure, with the impending signing of an executive order that will criminalise the destruction of fibre-optic cables.
• The regulation may marginally improve operators' and investors' sentiment towards FTTx investment, although we note that the Sub-Sharan